{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:49:52Z","timestamp":1790012992133,"version":"4.0.1"},"update-to":[{"DOI":"10.1002\/14651858.cd011935","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000}}],"reference-count":204,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011935.pub2","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T10:42:36Z","timestamp":1578480156000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Intravesical Bacillus Calmette-Gu\u00e9rin versus mitomycin C for Ta and T1 bladder cancer"],"prefix":"10.1002","author":[{"given":"Stefanie","family":"Schmidt","sequence":"first","affiliation":[{"name":"UroEvidence@Deutsche Gesellschaft f\u00fcr Urologie; Martin-Buber-Str. 10 Berlin Germany 14163"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Kunath","sequence":"additional","affiliation":[{"name":"UroEvidence@Deutsche Gesellschaft f\u00fcr Urologie; Martin-Buber-Str. 10 Berlin Germany 14163"},{"name":"University Hospital Erlangen; Department of Urology; Krankenhausstrasse 12 Erlangen Germany 91054"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Coles","sequence":"additional","affiliation":[{"name":"Cardiff University Library Services; Velindre NHS Trust; Velindre Cancer Centre Whitchurch Cardiff UK CF14 2TL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desiree Louise","family":"Draeger","sequence":"additional","affiliation":[{"name":"UroEvidence@Deutsche Gesellschaft f\u00fcr Urologie; Martin-Buber-Str. 10 Berlin Germany 14163"},{"name":"University of Rostock; Department of Urology; Ernst-Heydemann-Strasse 7 Rostock Mecklenburg-Vorpommern Germany 18057"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura-Maria","family":"Krabbe","sequence":"additional","affiliation":[{"name":"UroEvidence@Deutsche Gesellschaft f\u00fcr Urologie; Martin-Buber-Str. 10 Berlin Germany 14163"},{"name":"University of Muenster Medical Center; Department of Urology; Albert-Schweitzer Campus 1, GB A1 Muenster NRW Germany 48149"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Dersch","sequence":"additional","affiliation":[{"name":"Medical Center - University of Freiburg; Department of Neurology and Neurophysiology; Berliner Allee 29 Freiburg Germany 79110"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Kilian","sequence":"additional","affiliation":[{"name":"University of Heidelberg; Institute of Medical Biometry and Informatics; Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Jensen","sequence":"additional","affiliation":[{"name":"University of Heidelberg; Institute of Medical Biometry and Informatics; Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Dahm","sequence":"additional","affiliation":[{"name":"Minneapolis VA Health Care System; Urology Section; One Veterans Drive Mail Code 112D Minneapolis Minnesota USA 55417"},{"name":"University of Minnesota; Department of Urology; 420 Delaware Street SE MMC 394 Minneapolis Minnesota USA 55455"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg J","family":"Meerpohl","sequence":"additional","affiliation":[{"name":"Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg; Institute for Evidence in Medicine; Breisacher Str. 153 Freiburg Germany D-79110"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,1,8]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD011935.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/01.ju.0000080568.91703.18","article-title":"Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study","volume":"170","author":"Stasi","year":"2003","journal-title":"Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD011935.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.eururo.2007.02.063","article-title":"Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Gu\u00e9rin (BCG) in patients with non-muscle-invasive bladder carcinoma","volume":"52","author":"Friedrich","year":"2007","journal-title":"European Urology"},{"issue":"5","key":"10.1002\/14651858.CD011935.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s00120-008-1671-z","article-title":"Comparison of the effectiveness between long-term instillation of mitomycin C and short-term prophylaxis with MMC or bacille Calmette-Gu\u00e9rin. Study of patients with non-muscle-invasive urothelial cancer of the urinary bladder","volume":"47","author":"Isbarn","year":"2008","journal-title":"Urologe"},{"issue":"3","key":"10.1002\/14651858.CD011935.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S0022-5347(01)65673-8","article-title":"A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus Bacillus Calmette-Guerin","volume":"156","author":"Krege","year":"1996","journal-title":"Journal of Urology"},{"issue":"3","key":"10.1002\/14651858.CD011935.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/1078-1439(95)00041-F","article-title":"Randomized intergroup comparison of Bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study","volume":"1","author":"Lamm","year":"1995","journal-title":"Urologic Oncology"},{"issue":"4","key":"10.1002\/14651858.CD011935.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1464-410X.2006.06706.x","article-title":"Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and Bacillus Calmette-Gu\u00e9rin in patients with high-risk bladder cancer","volume":"99","author":"Gardmark","year":"2007","journal-title":"BJU International"},{"issue":"4","key":"10.1002\/14651858.CD011935.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-5347(18)37539-6","article-title":"Long term follow up of a randomised study of BCG versus mitomycin-C in high risk superficial bladder cancer","volume":"171","author":"Gardmark","year":"2004","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0008|cit8","first-page":"34","article-title":"Comparative study of mitomycin-C and BCG in treatment of superficial bladder cancer","volume":"164 Suppl","author":"Lundholm","year":"1994","journal-title":"Scandinavian Journal of Urology and Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD011935.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0022-5347(01)65853-1","article-title":"A randomized prospective study comparing long-term intravesical instillations of mitomycin C and Bacillus Calmette-Guerin in patients with superficial bladder carcinoma","volume":"156","author":"Lundholm","year":"1996","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0010|cit10","first-page":"9","article-title":"A five-year follow-up of a randomized prospective study comparing long-term intravesical instillations of mitomycin-C and Bacille Calmette-Guerin in patients with superficial bladder carcinoma","volume":"Suppl 197","author":"Malmstr\u00f6m","year":"1998","journal-title":"Scandinavian Journal of Urology and Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD011935.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(01)61607-0","article-title":"5-year followup of a randomized prospective study comparing mitomycin C and Bacillus Calmette-Guerin in patients with superficial bladder carcinoma","volume":"161","author":"Malmstr\u00f6m","year":"1999","journal-title":"Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD011935.pub2-BIB0012|cit12","first-page":"167","article-title":"A randomized prospective study of intravesical prophylaxis in non-muscle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy","volume":"80","author":"Mangiarotti","year":"2008","journal-title":"Archivio Italiano di Urologia, Andrologia"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0013|cit13","first-page":"S130","article-title":"Intravesical chemotherapy or immunotherapy for intermediate-risk non-muscle invasive bladder cancer: does the patient mention a different quality of life?","volume":"82","author":"Michielsen","year":"2013","journal-title":"Urology"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0014|cit14","unstructured":"NCT00974818 A randomized prospective study of intravesical prophylaxis in non-muscle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy clinicaltrials.gov\/ct2\/show\/NCT00974818"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0015|cit15","first-page":"Abstract 119","article-title":"A multicenter and randomised prospective study comparing three intravesical therapies, two with Bacillus Calmette-Guerin and one with mitomycin C chemotherapy in medium and low risk superficial bladders tumours","volume":"Suppl 5","author":"Nogueira March","year":"2001","journal-title":"European Urology"},{"issue":"5","key":"10.1002\/14651858.CD011935.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.eururo.2007.04.062","article-title":"A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose Bacillus Calmette-Guerin (27 mg) versus very low-dose Bacillus Calmette-Guerin (13.5 mg) versus mitomycin C","volume":"52","author":"Ojea","year":"2007","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0017|cit17","first-page":"Abstract 119","article-title":"A multicenter and randomised prospective study comparing three intravesical therapies, two with Bacillus Calmette-Guerin and one with mitomycin C chemotherapy in medium and low risk superficial bladders tumours","volume":"Suppl 5","author":"Nogueira March","year":"2001","journal-title":"European Urology"},{"issue":"5","key":"10.1002\/14651858.CD011935.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.eururo.2007.04.062","article-title":"A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose Bacillus Calmette-Guerin (27 mg) versus very low-dose Bacillus Calmette-Guerin (13.5 mg) versus mitomycin C","volume":"52","author":"Ojea","year":"2007","journal-title":"European Urology"},{"issue":"2","key":"10.1002\/14651858.CD011935.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2009.04.009","article-title":"Long-term efficacy of maintenance Bacillus Calmette-Gu\u00e9rin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up","volume":"56","author":"J\u00e4rvinen","year":"2009","journal-title":"European Urology"},{"issue":"1","key":"10.1002\/14651858.CD011935.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000471653","article-title":"Intravesical chemotherapy (mitomycin C) versus immunotherapy (Bacillus Calmette-Gu\u00e9rin) in superficial bladder cancer","volume":"20","author":"Rintala","year":"1991","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0021|cit21","first-page":"271","article-title":"Mitomycin-C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. FinnBladder Research Group","volume":"310","author":"Rintala","year":"1989","journal-title":"Progress in Clinical and Biological Research"},{"issue":"4","key":"10.1002\/14651858.CD011935.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1464-410X.1994.tb07604.x","article-title":"Prognostic factors in pTa-pT1 superficial bladder tumours treated with intravesical instillations. The Dutch South-Eastern Urological Collaborative Group","volume":"73","author":"Mulders","year":"1994","journal-title":"British Journal of Urology"},{"issue":"3 Pt 2","key":"10.1002\/14651858.CD011935.pub2-BIB0023|cit23","first-page":"929","article-title":"A randomized study of intravesical mitomycin C, Bacillus Calmette-Guerin Tice and Bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder","volume":"153","author":"Vegt","year":"1995","journal-title":"Journal of Urology"},{"issue":"12","key":"10.1002\/14651858.CD011935.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/0959-8049(93)90102-L","article-title":"A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group","volume":"29A","author":"Witjes","year":"1993","journal-title":"European Journal of Cancer"},{"issue":"S1","key":"10.1002\/14651858.CD011935.pub2-BIB0025|cit25","first-page":"10","article-title":"Update on the Dutch Cooperative Trial: mitomycin versus Bacillus Calmette-Gu\u00e9rin-Tice versus Bacillus Calmette-Gu\u00e9rin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder","volume":"14","author":"Witjes","year":"1996","journal-title":"Seminars in Urologic Oncology"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0026|cit26","first-page":"59","article-title":"BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale, design, and interim analysis of the trial of the South-East Cooperative Urological Group, The Netherlands","volume":"378","author":"Witjes","year":"1992","journal-title":"Progress in Clinical and Biological Research"},{"issue":"4","key":"10.1002\/14651858.CD011935.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1464-410X.1994.tb07604.x","article-title":"Prognostic factors in pTa-pT1 superficial bladder tumours treated with intravesical instillations. The Dutch South-Eastern Urological Collaborative Group","volume":"73","author":"Mulders","year":"1994","journal-title":"British Journal of Urology"},{"issue":"3 Pt 2","key":"10.1002\/14651858.CD011935.pub2-BIB0028|cit28","first-page":"929","article-title":"A randomized study of intravesical mitomycin C, Bacillus Calmette-Guerin Tice and Bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder","volume":"153","author":"Vegt","year":"1995","journal-title":"Journal of Urology"},{"issue":"12","key":"10.1002\/14651858.CD011935.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/0959-8049(93)90102-L","article-title":"A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group","volume":"29A","author":"Witjes","year":"1993","journal-title":"European Journal of Cancer"},{"issue":"S1","key":"10.1002\/14651858.CD011935.pub2-BIB0030|cit30","first-page":"10","article-title":"Update on the Dutch Cooperative Trial: mitomycin versus Bacillus Calmette-Gu\u00e9rin-Tice versus Bacillus Calmette-Gu\u00e9rin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder","volume":"14","author":"Witjes","year":"1996","journal-title":"Seminars in Urologic Oncology"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0031|cit31","first-page":"59","article-title":"BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale, design, and interim analysis of the trial of the South-East Cooperative Urological Group, The Netherlands","volume":"378","author":"Witjes","year":"1992","journal-title":"Progress in Clinical and Biological Research"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0032|cit32","first-page":"435","article-title":"BCG-(RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer. EORTC GU Group and the Dutch South-East Collaborative Group","volume":"303","author":"DeBruyne","year":"1989","journal-title":"Progress in Clinical and Biological Research"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD011935.pub2-BIB0033|cit33","first-page":"20","article-title":"BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer. First results of randomized prospective trial","volume":"31","author":"DeBruyne","year":"1988","journal-title":"Urology"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0034|cit34","first-page":"511","article-title":"BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer","volume":"269","author":"Debruyne","year":"1988","journal-title":"Progress in Clinical and Biological Research"},{"issue":"3","key":"10.1002\/14651858.CD011935.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0090-4295(98)00212-X","article-title":"Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Gu\u00e9rin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group","volume":"52","author":"Witjes","year":"1998","journal-title":"Urology"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0036|cit36","first-page":"285","article-title":"BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale and design of the trial of the Southeast Co-operative Urological Group, The Netherlands","volume":"310","author":"Meijden","year":"1989","journal-title":"Progress in Clinical and Biological Research"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0037|cit37","unstructured":"ACTRN12613000513718 Adding mitomycin C to Bacillus of Calmette-Guerin (BCG) as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase 3 trial www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=364165"},{"issue":"5","key":"10.1002\/14651858.CD011935.pub2-BIB0038|cit38","first-page":"424","article-title":"Preliminary results of a multicenter study with mitomycin C in superficial bladder tumors (Ta, T1)","volume":"12","author":"Allona Moncada","year":"1988","journal-title":"Actas Urologicas Espanolas"},{"issue":"1","key":"10.1002\/14651858.CD011935.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1023\/A:1007199932271","article-title":"The best management of superficial bladder tumours: comparing TUR alone versus TUR combined with intravesical chemotherapy modalities?","volume":"32","author":"Altay","year":"2000","journal-title":"International Urology and Nephrology"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0040|cit40","first-page":"S45","article-title":"Results of a randomized controlled trial comparing intravesical combined chemohyperthermia with mitomycin-C versus BCG for adjuvant treatment of patients with intermediate and high risk non-muscle invasive bladder cancer","volume":"1","author":"Arends","year":"2014","journal-title":"Urology"},{"issue":"2","key":"10.1002\/14651858.CD011935.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"944e","DOI":"10.1016\/S1569-9056(15)60932-0","article-title":"Results of the first randomized controlled trial comparing intravesical radiofrequency induced chemohyperthermia with mitomycin-C versus BCG for adjuvant treatment of patients with intermediate- and high-risk non-muscle invasive bladder cancer","volume":"14","author":"Arends","year":"2015","journal-title":"European Urology, Supplements"},{"issue":"6","key":"10.1002\/14651858.CD011935.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","article-title":"Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus Bacillus Calmette-Guerin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer","volume":"69","author":"Arends","year":"2016","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1464-410X.2009.09152.x","article-title":"Is immediate postoperative intravesical chemotherapy beneficial in non-muscle-invasive bladder cancer?","volume":"105 Suppl","author":"Ayres","year":"2010","journal-title":"British Journal of Urology"},{"issue":"5","key":"10.1002\/14651858.CD011935.pub2-BIB0044|cit44","first-page":"5890","article-title":"Maximizing intravesical therapy options: is there an advantage to the administration of perioperative mitomycin C prior to an induction course of BCG?","volume":"18","author":"Badalato","year":"2011","journal-title":"Canadian Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD011935.pub2-BIB0045|cit45","first-page":"181","article-title":"Superficial bladder neoplasia unresponsive to endocavitary treatment: when should the treatment approach be changed?","volume":"73","author":"Bassi","year":"2001","journal-title":"Archivio Italiano di Urologia"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011935.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1007\/s00761-004-0664-9","article-title":"Adjuvant and neoadjuvant therapy of urinary bladder carcinoma","volume":"10","author":"Bismarck","year":"2004","journal-title":"Onkologe"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD011935.pub2-BIB0047|cit47","first-page":"149","article-title":"Local immunoprophylaxis with BCG versus local chemoprophylaxis with doxorubicin or mitomycin C in the prevention of recurrence of superficial bladder cancer: comparative study","volume":"5","author":"Boccafoschi","year":"1991","journal-title":"Acta Urologica Italica"},{"issue":"9","key":"10.1002\/14651858.CD011935.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/ncponc0588","article-title":"Intravesical Bacillus Calmette-Guerin combined with electromotive mitomycin for high-risk superficial bladder cancer","volume":"3","author":"Bochner","year":"2006","journal-title":"Nature Clinical Practice Oncology"},{"issue":"1","key":"10.1002\/14651858.CD011935.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1590\/S1677-55382007000100025","article-title":"A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose Bacillus Calmette-Guerin (27 mg) versus very low-dose Bacillus Calmette-Guerin (13.5 mg) versus mitomycin C","volume":"34","author":"Bohle","year":"2008","journal-title":"International Braz J Urol"},{"issue":"9B","key":"10.1002\/14651858.CD011935.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/j.1464-410X.2008.07968.x","article-title":"Risk-adapted use of intravesical immunotherapy","volume":"102","author":"Braasch","year":"2008","journal-title":"BJU International"},{"issue":"2","key":"10.1002\/14651858.CD011935.pub2-BIB0051|cit51","first-page":"131","article-title":"Immunotherapy with BCG in high risk recurrent bladder cancers previously treated with multiple cycles of chemotherapy: long-term results","volume":"12","author":"Brausi","year":"1998","journal-title":"Acta Urologica Italica"},{"issue":"4","key":"10.1002\/14651858.CD011935.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.urolonc.2010.06.012","article-title":"A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer","volume":"30","author":"Chen","year":"2012","journal-title":"Urologic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD011935.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1055\/a-0750-5595","article-title":"Comparison of Different Treatment Schedules of Mitomycin C Intravesical Instillation in High-Risk Superficial Bladder Cancer Patients","volume":"50","author":"Chen","year":"2019","journal-title":"Aktuelle Urologie"},{"issue":"4","key":"10.1002\/14651858.CD011935.pub2-BIB0054|cit54","first-page":"1493","article-title":"Adjuvant intravesical instillation for primary T1G3 bladder cancer: BCG versus MMC in Korea","volume":"32","author":"Cho","year":"2012","journal-title":"Anticancer Research"},{"issue":"3","key":"10.1002\/14651858.CD011935.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/00005392-199503001-00011","article-title":"Randomized study of intravesical mitomycin-C, Bacillus-Calmette-Guerin, Tice and Bacillus-Calmette-Guerin, RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in-situ of bladder - comment","volume":"153","author":"Crawford","year":"1995","journal-title":"Journal of Urology"},{"issue":"2","key":"10.1002\/14651858.CD011935.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"257-8; discussi","DOI":"10.1016\/j.eururo.2009.04.041","article-title":"Is intravesical Bacillus Calmette-Guerin better than mitomycin for intermediate-risk bladder cancer?","volume":"56","author":"Dalbagni","year":"2009","journal-title":"European Urology"},{"issue":"4","key":"10.1002\/14651858.CD011935.pub2-BIB0057|cit57","first-page":"269","article-title":"The course of 203 superficial urothelial malignant tumors of the bladder during conservative treatment","volume":"23","author":"Jong","year":"1989","journal-title":"Annales d'Urologie"},{"issue":"5","key":"10.1002\/14651858.CD011935.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1159\/000020198","article-title":"The prognostic significance of S-phase analysis in stage Ta\/T1 bladder cancer. A Southwest Oncology Group Study","volume":"37","author":"deVere White","year":"2000","journal-title":"European Urology"},{"issue":"14","key":"10.1002\/14651858.CD011935.pub2-BIB0059|cit59","first-page":"391S","article-title":"Sequential Bacillus Calmette Guerin and electromotive mitomycin-C versus Bacillus Calmette Guerin alone for high-risk superficial bladder cancer: a prospective controlled study","volume":"22","author":"Stasi","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD011935.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0022-5347(18)37542-6","article-title":"Sequential intravesical Bacillus Calmette Guerin and electromotive mitomycin-C for high risk superficial bladder cancer: a prospective controlled study","volume":"171","author":"Stasi","year":"2004","journal-title":"Journal of Urology"},{"issue":"1","key":"10.1002\/14651858.CD011935.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial","volume":"7","author":"Stasi","year":"2006","journal-title":"Lancet Oncology"},{"issue":"2","key":"10.1002\/14651858.CD011935.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1569-9056(06)60679-9","article-title":"Long-term follow-up of a randomised trial comparing sequential Bacillus Calmette-Guerin and electromotive mitomycin-C with Bacillus Calmette Guerin alone in high-risk superficial bladder cancer","volume":"5","author":"Stasi","year":"2006","journal-title":"European Urology Supplements"},{"issue":"4","key":"10.1002\/14651858.CD011935.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0022-5347(18)33066-0","article-title":"Sequential Bacillus Calmette-Guerin and electromotive mitomycin-C versus Bacillus Calmette-Guerin alone for high risk superficial bladder cancer: long-term follow-up results of a prospective controlled study","volume":"175","author":"Stasi","year":"2006","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0064|cit64","first-page":"e674","article-title":"Intravesical sequential Bacillus Calmette-Guerin and electromotive mitomycin versus Bacillus Calmette-Guerin alone for stage PT1 urothelial bladder cancer","volume":"1","author":"Stasi","year":"2012","journal-title":"Journal of Urology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011935.pub2-BIB0065|cit65","first-page":"15","article-title":"Intravesical sequential BCG and electromotive mitomycin versus BCG alone in high risk non-muscle invasive bladder cancer","volume":"30","author":"Stasi","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD011935.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"e698","DOI":"10.1016\/S1569-9056(13)61180-X","article-title":"Intravesical sequential BCG and electromotive mitomycin versus BCG alone for stage pT1 urothelial bladder cancer","volume":"12","author":"Stasi","year":"2013","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0067|cit67","first-page":"e381","article-title":"Is intravesical BCG alone still the only truly effective intravesical therapy for non-muscle invasive bladder cancer?","volume":"1","author":"Stasi","year":"2015","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0068|cit68","first-page":"e567","article-title":"Immediate mitomycin C instillation followed by usual BCG course versus usual BCG alone for superficial transitional cell carcinoma of the bladder (4 years experience)","volume":"1","author":"Kader","year":"2010","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0069|cit69","unstructured":"EUCTR2008-005428-99-GB A randomised controlled phase III trial comparing hyperthermia plus mitomycin to a second course of Bacillus Calmette-Guerin or standard therapy in patients with recurrence of non-muscle invasive bladder cancer following induction or maintenance Bacillus Calmette-Guerin therapy. Hyperthermia plus mitomycin (HYMN) www.clinicaltrialsregister.eu\/ctr-search\/trial\/2008-005428-99\/GB"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0070|cit70","unstructured":"EUCTR2011-000607-41-BE A phase I\/II multicentric Belgian prospective novel sequential chemo-immunotherapy regimen for adjuvant treatment in non-muscle invasive bladder cancer. Novel chemo-immunotherapy for non-muscle invasive bladder cancer apps.who.int\/trialsearch\/Trial3.aspx?trialid=EUCTR2011-000607-41-BE"},{"issue":"4","key":"10.1002\/14651858.CD011935.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2015.04.006","article-title":"Long-term outcomes of the FinnBladder-4 study","volume":"68","author":"Svatek","year":"2015","journal-title":"European Urology"},{"issue":"5","key":"10.1002\/14651858.CD011935.pub2-BIB0074|cit72","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1097\/00005392-199811000-00018","article-title":"Results of a randomized phase III trial of sequential, intravesical therapy with mitomycin C and Bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer - comment","volume":"160","author":"Rintala","year":"1998","journal-title":"Journal of Urology"},{"issue":"1","key":"10.1002\/14651858.CD011935.pub2-BIB0072|cit73","doi-asserted-by":"crossref","first-page":"56-9; discussio","DOI":"10.1016\/S0022-5347(01)65936-6","article-title":"Alternating mitomycin C and Bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. FinnBladder Group","volume":"156","author":"Rintala","year":"1996","journal-title":"Journal of Urology"},{"issue":"6","key":"10.1002\/14651858.CD011935.pub2-BIB0073|cit74","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/S0022-5347(01)66691-6","article-title":"Alternating mitomycin C and Bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The FinnBladder Group","volume":"154","author":"Rintala","year":"1995","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0075|cit75","first-page":"644","article-title":"Instillation of BCG vaccine and mitomycin for the prevention of bladder neoplasms recurrence","volume":"6","author":"Gao","year":"2002","journal-title":"China Journal of Cancer Prevention and Treatment"},{"issue":"2","key":"10.1002\/14651858.CD011935.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1464-410X.2008.08342.x","article-title":"A chemosensitivity test to individualize intravesical treatment for non-muscle-invasive bladder cancer","volume":"104","author":"Gazzaniga","year":"2009","journal-title":"BJU International"},{"issue":"5","key":"10.1002\/14651858.CD011935.pub2-BIB0077|cit77","first-page":"379","article-title":"A prospective and randomized study of the complete response, index of recurrences and progression in superficial bladder carcinoma treated with mitomycin C alone versus mitomycin C and BCG alternatively","volume":"46","author":"Gelabert-Mas","year":"1993","journal-title":"Archivos Espanoles de Urologia"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011935.pub2-BIB0078|cit78","first-page":"34","article-title":"Six years of follow up. A prospective study on intravesical chemoprophylaxis with mitomycin-C and BCG alternating. Complete response rate and much lower tumor progression rate","volume":"80","author":"Gelabert-Mas","year":"1997","journal-title":"British Journal of Urology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011935.pub2-BIB0079|cit79","first-page":"40","article-title":"BCG vs mitomycin in patients affected by monocentric T1G2 bladder cancer: randomized study in diploid and aneuploid TCC","volume":"80","author":"Gianneo","year":"1997","journal-title":"British Journal of Urology"},{"issue":"3","key":"10.1002\/14651858.CD011935.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.urolonc.2006.02.007","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial","volume":"24","author":"Grossman","year":"2006","journal-title":"Urologic Oncology: Seminars and Original Investigations"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0081|cit81","doi-asserted-by":"crossref","unstructured":"Gonzalez Padilla DA Gonzalez Diaz A Miranda-Utrera N De La Rosa Kehrmann F Villacampa-Auba F Guerrero-Ramos F HIVEC HR: Chemohyperthermia with mitomycin C vs BCG for high-risk non-muscle invasive bladder cancer. Preliminary results from a randomized controlled trial European Urology 2019 e768 e770","DOI":"10.1016\/S1569-9056(19)30563-9"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0082|cit82","doi-asserted-by":"crossref","unstructured":"Guerrero-Ramos F Gonzalez-Padilla DA Gonzalez-Diaz A Duarte-Ojeda JM Miranda-Utrera N Villacampa-Auba F de la Rosa-Kehrmann F BCG VS CHEMOHYPERTHERMIA WITH MITOMYCIN C FOR HIGH-RISK NON-MUSCLE INVASIVE BLADDER CARCINOMA: PRELIMINARY RESULTS OF HIVEC-HR RANDOMIZED CLINICAL TRIAL Journal of Urology 2019 E620 E620","DOI":"10.1097\/01.JU.0000556231.44325.78"},{"issue":"4","key":"10.1002\/14651858.CD011935.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1590\/S1677-55382012000400006","article-title":"The value of perioperative mitomycin C instillation in improving subsequent Bacillus Calmette-Guerin instillation efficacy in intermediate and high-risk patients with non-muscle invasive bladder cancer: a prospective randomized study","volume":"38","author":"Gulpinar","year":"2012","journal-title":"International Braz J Urol"},{"issue":"3","key":"10.1002\/14651858.CD011935.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3346\/jkms.2015.30.3.252","article-title":"Is intravesical Bacillus Calmette-Gu\u00e9rin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate","volume":"30","author":"Han","year":"2015","journal-title":"Journal of Korean Medical Science"},{"issue":"1","key":"10.1002\/14651858.CD011935.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.ju.0000063685.29339.24","article-title":"Effect of intravesical treatment of transitional cell carcinoma with Bacillus Calmette-Guerin and mitomycin C on urinary survival levels and outcome","volume":"170","author":"Hausladen","year":"2003","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0086|cit86","first-page":"25","article-title":"Sequential BCG and mitomycin intravesical therapy versus BCG alone for high-risk non-muscle invasive bladder cancer (NMIBC): pilot study and proposal for a 2-stage randomized phase III trial","volume":"107","author":"Hayne","year":"2011","journal-title":"BJU International"},{"issue":"4","key":"10.1002\/14651858.CD011935.pub2-BIB0087|cit87","first-page":"419","article-title":"Clinical trial of effect and adverse reaction of domestic therapeutic BCG for prevention of recurrence of superficial bladder cancer","volume":"23","author":"Huang","year":"2010","journal-title":"Chinese Journal of Biologicals"},{"issue":"5","key":"10.1002\/14651858.CD011935.pub2-BIB0088|cit88","first-page":"289","article-title":"A comparative study of BCG and mitomycin C in superficial carcinomas of the bladder","volume":"17","author":"Iavarone","year":"1996","journal-title":"Giornale di Chirurgia"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0089|cit89","unstructured":"ISRCTN85785327 HYMN: a trial comparing hyperthermia and mitomycin chemotherapy with a second BCG treatment, or other standard treatment, for bladder cancer that has come back www.isrctn.com\/ISRCTN85785327"},{"issue":"6","key":"10.1002\/14651858.CD011935.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3109\/00365599.2012.694906","article-title":"Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and Bacillus Calmette-Guerin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17-year follow-up","volume":"46","author":"Jarvinen","year":"2012","journal-title":"Scandinavian Journal of Urology and Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD011935.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/j.juro.2013.08.070","article-title":"Re: long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and Bacillus Calmette-Gu\u00e9rin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17-year follow-up","volume":"190","author":"Jarvinen","year":"2013","journal-title":"Journal of Urology"},{"issue":"1","key":"10.1002\/14651858.CD011935.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"e1107","DOI":"10.1016\/S1569-9056(14)61087-3","article-title":"15-year outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma (NMIBC) treated with 5 weekly mitomycin C (MMC) instillations followed by monthly Bacillus-Calmette Guerin (BCG) or alternating BCG and interferon-alpha2b (IFN) instillations","volume":"13","author":"Jarvinen","year":"2014","journal-title":"European Urology"},{"issue":"4","key":"10.1002\/14651858.CD011935.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.eururo.2015.02.022","article-title":"Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly Bacillus Calmette-Gu\u00e9rin (BCG) or alternating BCG and interferon-\u03b12b instillations: prospective randomised FinnBladder-4 study","volume":"68","author":"Jarvinen","year":"2015","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0094|cit94","first-page":"31","article-title":"Superficial urinary bladder cancer. Results from the FinnBladder studies and a review on instillation treatments","volume":"206","author":"Jauhiainen","year":"1993","journal-title":"Annales Chirurgiae et Gynaecologiae"},{"issue":"1","key":"10.1002\/14651858.CD011935.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0022-5347(05)67446-0","article-title":"Weekly mitomycin C followed by monthly Bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and Bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma","volume":"164","author":"Kaasinen","year":"2000","journal-title":"Journal of Urology"},{"issue":"2","key":"10.1002\/14651858.CD011935.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0302-2838(02)00260-9","article-title":"Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma","volume":"42","author":"Kaasinen","year":"2002","journal-title":"European Urology"},{"issue":"6","key":"10.1002\/14651858.CD011935.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0302-2838(03)00140-4","article-title":"Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a Nordic study","volume":"43","author":"Kaasinen","year":"2003","journal-title":"European Urology"},{"issue":"1","key":"10.1002\/14651858.CD011935.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"e1006","DOI":"10.1016\/S1569-9056(14)60989-1","article-title":"17 year follow-up of the Nordic CIS study: long-term results of 1 year BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder","volume":"13","author":"Kaasinen","year":"2014","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0099|cit99","first-page":"12","article-title":"HYMN: a randomised controlled phase III trial comparing hyperthermia plus mitomycin to a second course of BCG or institutional standard in patients with recurrence of non-muscle invasive bladder cancer (NMIBC) following induction or maintenance BCG therapy","volume":"115","author":"Kelly","year":"2015","journal-title":"BJU International"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0100|cit100","first-page":"e568","article-title":"Sequential chemo-immunotherapy with mitomycin C (MMC) and Bacillus Calmette-Guerin (BCG) versus BCG alone in patients with carcinoma in situ (CIS) of the urinary bladder. Results of EORTC GU group randomized phase II study 30993","volume":"1","author":"Kirkali","year":"2010","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000052386","article-title":"Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group","volume":"37 Suppl 3","author":"Kurth","year":"2000","journal-title":"European Urology"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD011935.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/0090-4295(91)80136-U","article-title":"Comparison of BCG with other intravesical agents","volume":"37","author":"Lamm","year":"1991","journal-title":"Urology"},{"issue":"6","key":"10.1002\/14651858.CD011935.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/S0022-5347(05)68075-5","article-title":"Long-term followup of initial Ta grade 1 transitional cell carcinoma of the bladder","volume":"162","author":"Leblanc","year":"1999","journal-title":"Journal of Urology"},{"issue":"5","key":"10.1002\/14651858.CD011935.pub2-BIB0104|cit104","first-page":"1861","article-title":"Intravesical sequential BCG and electromotive mitomycin-C versus BCG alone for stage PT1 urothelial bladder cancer","volume":"32","author":"Liberati","year":"2012","journal-title":"Anticancer Research"},{"issue":"4","key":"10.1002\/14651858.CD011935.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(01)61607-0","article-title":"5-Year followup of a randomized prospective study comparing mitomycin C and Bacillus Calmette-Guerin in patients with superficial bladder carcinoma","volume":"161","author":"Lundholm","year":"1999","journal-title":"Journal of Urology"},{"issue":"2","key":"10.1002\/14651858.CD011935.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.eururo.2009.05.025","article-title":"Rebuttal from authors re: Guido Dalbagni. Is intravesical Bacillus Calmette-Gu\u00e9rin better than mitomycin for intermediate-risk bladder cancer?","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"European Urology"},{"issue":"6","key":"10.1002\/14651858.CD011935.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.urology.2009.09.088","article-title":"Late recurrence and progression in non-muscle-invasive bladder cancers after 5-year tumor-free periods","volume":"75","author":"Matsumoto","year":"2010","journal-title":"Urology"},{"issue":"11 Pt B","key":"10.1002\/14651858.CD011935.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"E508","DOI":"10.1111\/j.1464-410X.2012.11194.x","article-title":"Risk of subsequent tumour recurrence and stage progression in bacille Calmette-Guerin relapsing non-muscle-invasive bladder cancer","volume":"110","author":"Matsumoto","year":"2012","journal-title":"BJU International"},{"issue":"1","key":"10.1002\/14651858.CD011935.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3329\/bjms.v15i1.19161","article-title":"Prospective randomized study between intravesical BCG and mitomycin-C for non-muscle-invasive urothelial carcinoma of urinary-bladder post TURBT","volume":"15","author":"Mondal","year":"2016","journal-title":"Bangladesh Journal of Medical Science"},{"issue":"5","key":"10.1002\/14651858.CD011935.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0022-5347(05)68976-8","article-title":"Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and Bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer","volume":"161","author":"Morales","year":"1999","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0111|cit111","unstructured":"Murillo I Barja S Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03982797 2019"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0112|cit112","unstructured":"NCT00023842 BCG with or without mitomycin in treating patients with bladder cancer clinicaltrials.gov\/ct2\/show\/NCT00023842"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0113|cit113","unstructured":"NCT00384891 Hyperthermia treatment in conjunction with mitomycin C versus BCG for superficial bladder cancer clinicaltrials.gov\/ct2\/show\/NCT00384891"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0114|cit114","unstructured":"NCT01094964 Hyperthermia and mitomycin C, Bacillus Calmette-Guerin, or standard therapy as second-line therapy in treating patients with recurrent bladder cancer clinicaltrials.gov\/ct2\/show\/NCT01094964"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0115|cit115","unstructured":"NCT01442519 Sequential Bacillus Calmette-Gu\u00e9rin (BCG) and electromotive mitomycin-C versus Bacillus Calmette-Gu\u00e9rin (BCG) alone for high risk superficial bladder cancer clinicaltrials.gov\/ct2\/show\/NCT01442519"},{"issue":"4","key":"10.1002\/14651858.CD011935.pub2-BIB0116|cit116","first-page":"362","article-title":"Clinical study of intravesical instillation therapy for superficial bladder cancer","volume":"58","author":"Nishimura","year":"1996","journal-title":"Journal of Urology"},{"issue":"7","key":"10.1002\/14651858.CD011935.pub2-BIB0117|cit117","first-page":"689","article-title":"Resultados de un estudio prospective de quimioprofilaxis con mitomycina-C y BCG alternadas: respuesta completa, \u00cdndice de recidivas y de progresi\u00f3n","volume":"49","author":"Nohales","year":"1996","journal-title":"Archivos Espanoles de Urologia"},{"issue":"3","key":"10.1002\/14651858.CD011935.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/CAD.0000000000000456","article-title":"Final results of the phase III URO-BCG 4 multicenter study: efficacy and tolerance of one-third dose BCG maintenance in nonmuscle invasive bladder cancer","volume":"28","author":"Nouhaud","year":"2017","journal-title":"Anticancer Drugs"},{"issue":"1","key":"10.1002\/14651858.CD011935.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"e1; author repl","DOI":"10.1016\/j.eururo.2011.03.050","article-title":"Re: Willem Oosterlinck, Ziya Kirkali, Richard Sylvester, et al. Sequential intravesical chemoimmunotherapy with mitomycin C and Bacillus Calmette-Guerin and with Bacillus Calmette-Guerin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC Genito-urinary Group Randomized Phase 2 Trial (30993). Eur Urol 2011;59:438-46","volume":"60","author":"Ooi Wei","year":"2011","journal-title":"European Urology"},{"issue":"1","key":"10.1002\/14651858.CD011935.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1464-410X.2004.04556.x","article-title":"T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival","volume":"93","author":"Peyromaure","year":"2004","journal-title":"BJU International"},{"issue":"4","key":"10.1002\/14651858.CD011935.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.urology.2004.10.049","article-title":"Effects of intravesical chemotherapy and immunotherapy on semen analysis","volume":"65","author":"Raviv","year":"2005","journal-title":"Urology"},{"issue":"5","key":"10.1002\/14651858.CD011935.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/j.1464-410X.2006.06482.x","article-title":"Adjuvant intravesical therapy based on an in vitro cytotoxicity assay in the management of superficial transitional cell cancer of the urinary bladder","volume":"98","author":"Saxena","year":"2006","journal-title":"BJU International"},{"issue":"9","key":"10.1002\/14651858.CD011935.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1046\/j.1442-2042.2001.00355.x","article-title":"Equivalent efficacy of mitomycin C plus doxorubicin instillation to Bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder","volume":"8","author":"Sekine","year":"2001","journal-title":"International Journal of Urology"},{"issue":"11","key":"10.1002\/14651858.CD011935.pub2-BIB0124|cit124","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003231.pub2","article-title":"WITHDRAWN: Intravesical Bacillus Calmette-Guerin versus mitomycin C for Ta and T I bladder cancer","author":"Shelley","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD011935.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1009-13; discus","DOI":"10.1016\/S0090-4295(98)00374-4","article-title":"Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression","volume":"52","author":"Smits","year":"1998","journal-title":"Urology"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0126|cit126","first-page":"71","article-title":"Follow up of patients receiving treatment for superficial bladder cancer with mitomycin C and BCG","volume":"350","author":"Soloway","year":"1990","journal-title":"Progress in Clinical and Biological Research"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0127|cit127","unstructured":"Stasi SM Giannantoni A Stephen RL Capelli G Giurioli A Zampa G Sequential Bacillus Calmette Gu\u00e9rin and electromotive mitomycin-C versus Bacillus Calmette Gu\u00e9rin alone for high-risk superficial bladder cancer: a prospective controlled study Annual Meeting Proceedings of the American Society of Clinical Oncology 2004 390"},{"issue":"5","key":"10.1002\/14651858.CD011935.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.urolonc.2016.11.016","article-title":"Bacillus Calmette-Guerin strain may not effect recurrence-free survival when used intravesically with interferon-alpha2b for non-muscle-invasive bladder cancer","volume":"35","author":"Steinberg","year":"2017","journal-title":"Urologic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD011935.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.eururo.2010.11.038","article-title":"Sequential intravesical chemoimmunotherapy with mitomycin C and Bacillus Calmette-Guerin and with Bacillus Calmette-Guerin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993)","volume":"59","author":"Oosterlinck","year":"2011","journal-title":"European Urology"},{"issue":"2","key":"10.1002\/14651858.CD011935.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1569-9056(10)60192-3","article-title":"Sequential chemo-immunotherapy with mitomycin C (MMC) and Bacillus Calmette-Guerin (BCG) versus BCG alone in patients with carcinoma in situ (CIS) of the urinary bladder results of EORTC GU group randomized phase II study 30993","volume":"9","author":"Oosterlinck","year":"2010","journal-title":"European Urology"},{"issue":"2","key":"10.1002\/14651858.CD011935.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"266-8; discussi","DOI":"10.1016\/j.eururo.2009.04.043","article-title":"Bacillus Calmette-Guerin versus mitomycin C for the treatment of intermediate-risk non-muscle-invasive bladder cancer: the debate continues","volume":"56","author":"Sylvester","year":"2009","journal-title":"European Urology"},{"issue":"3","key":"10.1002\/14651858.CD011935.pub2-BIB0132|cit132","first-page":"201","article-title":"Prevention of postoperative recurrence of human bladder carcinoma by intravesical instillation of immunotoxin, a clinical study","volume":"83","author":"Tong","year":"2003","journal-title":"Zhonghua Yi Xue za Zhi"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0133|cit133","first-page":"285","article-title":"BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale and design of the trial of the Southeast Co-operative Urological Group, The Netherlands","volume":"310","author":"Meijden","year":"1989","journal-title":"Progress in Clinical and Biological Research"},{"issue":"4","key":"10.1002\/14651858.CD011935.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0090-4295(99)80047-8","article-title":"Risk factors in carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group","volume":"45","author":"Gils-Gielen","year":"1995","journal-title":"Urology"},{"issue":"7","key":"10.1002\/14651858.CD011935.pub2-BIB0135|cit135","first-page":"410","article-title":"Intravesical BCG, mitomycin-C and thiotepa in the prevention of bladder tumor recurrence after operation","volume":"30","author":"Wang","year":"1992","journal-title":"Chinese Journal of Surgery"},{"issue":"4","key":"10.1002\/14651858.CD011935.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"P228","DOI":"10.1007\/s10330-011-0774-y","article-title":"Prospective clinical studies at the efficacy of Brucea javanica oil, mitomycin and BCG for preventing postoperative relapse of superficial bladder cancer through perfusion","volume":"10","author":"Wang","year":"2011","journal-title":"Chinese-German Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD011935.pub2-BIB0137|cit137","first-page":"622","article-title":"Efficacy of Brucea javanica oil, mitomycin and BCG for prophylaxis of recurrent superficial bladder cancer","volume":"17","author":"Wang","year":"2010","journal-title":"Chinese Journal of Cancer Prevention and Treatment"},{"issue":"5","key":"10.1002\/14651858.CD011935.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"1668-71; discus","DOI":"10.1016\/S0022-5347(01)62377-2","article-title":"Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and Bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer","volume":"160","author":"Witjes","year":"1998","journal-title":"Journal of Urology"},{"issue":"5","key":"10.1002\/14651858.CD011935.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0022-5347(01)62377-2","article-title":"Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and Bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer","volume":"160","author":"Witjes","year":"1999","journal-title":"Journal of Urology"},{"issue":"5","key":"10.1002\/14651858.CD011935.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0022-5347(05)68976-8","article-title":"Re: results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and Bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer (multiple letters)","volume":"161","author":"Witjes","year":"1999","journal-title":"Journal of Urology"},{"issue":"2","key":"10.1002\/14651858.CD011935.pub2-BIB0141|cit141","first-page":"290","article-title":"Intravesical instillation of Bacillus Calmette-Guerin for superficial bladder carcinoma: study on significance of additional maintenance instillations of Bacillus Calmette-Guerin","volume":"82","author":"Yabusaki","year":"1991","journal-title":"Nippon Hinyokika Gakkai Zasshi"},{"issue":"8","key":"10.1002\/14651858.CD011935.pub2-BIB0142|cit142","first-page":"464","article-title":"Prevention of postoperative recurrence of bladder cancer: a clinical study","volume":"37","author":"Yang","year":"1999","journal-title":"Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]"},{"issue":"6","key":"10.1002\/14651858.CD011935.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1569-9056(10)61437-6","article-title":"Comparison of full-dose intravesical BCG versus half dose BCG and mitomycin-C in treatment of patients with superficial bladder cancer","volume":"9","author":"Yari","year":"2010","journal-title":"European Urology"},{"issue":"4","key":"10.1002\/14651858.CD011935.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"477","DOI":"10.6004\/jnccn.2013.0060","article-title":"Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"11","author":"Abern","year":"2013","journal-title":"Journal of the National Comprehensive Cancer Network : JNCCN"},{"issue":"6","key":"10.1002\/14651858.CD011935.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/MOU.0000000000000544","article-title":"What to do during Bacillus Calmette-Gu\u00e9rin shortage? Valid strategies based on evidence","volume":"28","author":"Abufaraj","year":"2018","journal-title":"Current Opinion in Urology"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0146|cit146","volume-title":"Emerging Approaches to Diagnosis and Treatment of Non-Muscle-Invasive Bladder Cancer. AHRQ Publication No. 15(16)-EHC017-EF","author":"Chou","year":"2016"},{"issue":"6","key":"10.1002\/14651858.CD011935.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","article-title":"Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus Bacillus Calmette-Gu\u00e9rin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer","volume":"69","author":"Arends","year":"2016","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0148|cit148","volume-title":"EAU Guidelines on Non-Muscle-Invasive Bladder Cancer (TaT1 and CIS)","author":"Babjuk","year":"2018"},{"issue":"3","key":"10.1002\/14651858.CD011935.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/jrsm.1297","article-title":"Methods for evidence synthesis in the case of very few studies","volume":"9","author":"Bender","year":"2018","journal-title":"Research Synthesis Methods"},{"issue":"3","key":"10.1002\/14651858.CD011935.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.juro.2017.01.086","article-title":"Efficacy of Bacillus Calmette-Gu\u00e9rin strains for treatment of nonmuscle invasive bladder cancer: a systematic review and network meta-analysis","volume":"198","author":"Boehm","year":"2017","journal-title":"Journal of Urology"},{"issue":"2","key":"10.1002\/14651858.CD011935.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"European Urology"},{"issue":"1","key":"10.1002\/14651858.CD011935.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical Bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"B\u00f6hle","year":"2003","journal-title":"Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD011935.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacille Calmette-Gu\u00e9rin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"B\u00f6hle","year":"2004","journal-title":"Urology"},{"issue":"4","key":"10.1002\/14651858.CD011935.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.vaccine.2017.12.010","article-title":"Bacillus Calmette-Gu\u00e9rin (BCG) vaccine: a global assessment of demand and supply balance","volume":"36","author":"Cernuschi","year":"2018","journal-title":"Vaccine"},{"issue":"1","key":"10.1002\/14651858.CD011935.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1470-2045(13)70546-1","article-title":"Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5 - a population-based study","volume":"15","author":"Angelis","year":"2014","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0156|cit156","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"1","key":"10.1002\/14651858.CD011935.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial","volume":"7","author":"Stasi","year":"2006","journal-title":"Lancet Oncology"},{"issue":"4","key":"10.1002\/14651858.CD011935.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00345-011-0709-9","article-title":"Impact of gender on bladder cancer incidence, staging, and prognosis","volume":"29","author":"Fajkovic","year":"2011","journal-title":"World Journal of Urology"},{"issue":"6","key":"10.1002\/14651858.CD011935.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"European Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD011935.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1464-410X.2006.06706.x","article-title":"Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and Bacillus Calmette-Guerin in patients with high-risk bladder cancer","volume":"99","author":"Gardmark","year":"2007","journal-title":"BJU International"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0161|cit161","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT accessed Mai 2019"},{"issue":"5","key":"10.1002\/14651858.CD011935.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/ijcp.12075","article-title":"Current perspectives in bladder cancer management","volume":"67","author":"Griffiths","year":"2013","journal-title":"International Journal of Clinical Practice"},{"issue":"7651","key":"10.1002\/14651858.CD011935.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"GRADE: what is \"quality of evidence\" and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD011935.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0165|cit165","unstructured":"Higgins JP Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0166|cit166","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"9","key":"10.1002\/14651858.CD011935.pub2-BIB0167|cit167","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011864.pub2","article-title":"Intravesical electromotive drug administration for non-muscle invasive bladder cancer","author":"Jung","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD011935.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1080\/21681805.2016.1210672","article-title":"Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder","volume":"50","author":"Kaasinen","year":"2016","journal-title":"Scandinavian Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD011935.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance Bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study","volume":"163","author":"Lamm","year":"2000","journal-title":"Journal of Urology"},{"issue":"1","key":"10.1002\/14651858.CD011935.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2011.04.023","article-title":"The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review","volume":"60","author":"Lammers","year":"2011","journal-title":"European Urology"},{"issue":"2","key":"10.1002\/14651858.CD011935.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/0962280211432218","article-title":"Meta-analysis of incidence of rare events","volume":"22","author":"Lane","year":"2013","journal-title":"Statistical Methods in Medical Research"},{"issue":"2","key":"10.1002\/14651858.CD011935.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus Bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"European Urology"},{"issue":"5","key":"10.1002\/14651858.CD011935.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/iju.13538","article-title":"Bacillus Calmette-Gu\u00e9rin strain differences as the basis for immunotherapies against bladder cancer","volume":"25","author":"Miyazaki","year":"2018","journal-title":"International Journal of Urology"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0174|cit174","unstructured":"NCT02948543 Adding mitomycin C to Bacillus of Calmette-Guerin (BCG) as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer (BCG+MMC) clinicaltrials.gov\/ct2\/show\/NCT02948543"},{"issue":"3","key":"10.1002\/14651858.CD011935.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/cncr.30392","article-title":"Non-muscle-invasive bladder cancer: intravesical treatments beyond bacille Calmette-Gu\u00e9rin","volume":"123","author":"Packiam","year":"2017","journal-title":"Cancer"},{"issue":"24","key":"10.1002\/14651858.CD011935.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD011935.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.eururo.2013.06.009","article-title":"Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review","volume":"64","author":"Perlis","year":"2013","journal-title":"European Urology"},{"issue":"2","key":"10.1002\/14651858.CD011935.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0022-5347(17)44926-3","article-title":"The mechanism of human bladder tumor implantation in an in vitro model","volume":"136","author":"Pode","year":"1986","journal-title":"Journal of Urology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011935.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"24","DOI":"10.5301\/uro.5000193","article-title":"Mitomycin C: new strategies to improve efficacy of a well-known therapy","volume":"83","author":"Ragonese","year":"2016","journal-title":"Urologia"},{"issue":"4","key":"10.1002\/14651858.CD011935.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.eururo.2014.02.061","article-title":"Bacillus Calmette-Gu\u00e9rin strain differences have an impact on clinical outcome in bladder cancer immunotherapy","volume":"66","author":"Rentsch","year":"2014","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0181|cit181","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"11","key":"10.1002\/14651858.CD011935.pub2-BIB0182|cit182","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011935","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin versus mitomycin C for Ta and T1 bladder cancer","author":"Schmidt","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0183|cit183","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"1","key":"10.1002\/14651858.CD011935.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.juro.2013.01.084","article-title":"A prospective comparative study of intravesical Bacillus Calmette-Gu\u00e9rin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer","volume":"190","author":"Sengiku","year":"2013","journal-title":"Journal of Urology"},{"issue":"5","key":"10.1002\/14651858.CD011935.pub2-BIB0185|cit185","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006885.pub2","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin versus epirubicin for Ta and T1 bladder cancer","author":"Shang","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD011935.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1464-410X.2009.09076.x","article-title":"The effect of age and gender on bladder cancer: a critical review of the literature","volume":"105","author":"Shariat","year":"2010","journal-title":"BJU International"},{"issue":"3","key":"10.1002\/14651858.CD011935.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ctrv.2009.12.005","article-title":"Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses","volume":"36","author":"Shelley","year":"2010","journal-title":"Cancer Treatment Reviews"},{"issue":"1","key":"10.1002\/14651858.CD011935.pub2-BIB0188|cit188","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"3","key":"10.1002\/14651858.CD011935.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00345-009-0395-z","article-title":"Economic aspects of bladder cancer: what are the benefits and costs?","volume":"27","author":"Sievert","year":"2009","journal-title":"World Journal of Urology"},{"issue":"6","key":"10.1002\/14651858.CD011935.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1308\/003588414X13946184901001","article-title":"The effects and effectiveness of electromotive drug administration and chemohyperthermia for treating non-muscle invasive bladder cancer","volume":"96","author":"Slater","year":"2014","journal-title":"Annals of the Royal College of Surgeons of England"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0191|cit191","volume-title":"TNM Classification of Malignant Tumors","author":"Sobin","year":"2009"},{"issue":"5","key":"10.1002\/14651858.CD011935.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/1097-0142(19800901)46:5<1158::AID-CNCR2820460514>3.0.CO;2-E","article-title":"Urothelial susceptibility to tumor cell implantation: influence of cauterization","volume":"46","author":"Soloway","year":"1980","journal-title":"Cancer"},{"issue":"3","key":"10.1002\/14651858.CD011935.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2014.09.026","article-title":"Sequential combination of mitomycin C plus Bacillus Calmette-Gu\u00e9rin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial","volume":"67","author":"Solsona","year":"2016","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD011935.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2014.01.006","article-title":"The economics of bladder cancer: costs and considerations of caring for this disease","volume":"66","author":"Svatek","year":"2014","journal-title":"European Urology"},{"issue":"6 Pt 1","key":"10.1002\/14651858.CD011935.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1097\/01.ju.0000125486.92260.b2","article-title":"A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials","volume":"171","author":"Sylvester","year":"2004","journal-title":"Journal of Urology"},{"issue":"3","key":"10.1002\/14651858.CD011935.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.eururo.2009.06.028","article-title":"Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy","volume":"56","author":"Rhijn","year":"2009","journal-title":"European Urology"},{"issue":"22","key":"10.1002\/14651858.CD011935.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1002\/sim.1303","article-title":"Aggregate data meta-analysis with time-to-event outcomes","volume":"1","author":"Williamson","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD011935.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1471-2288-10-54","article-title":"Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial","volume":"10","author":"Woods","year":"2010","journal-title":"BMC Medical Research Methodology"},{"issue":"3","key":"10.1002\/14651858.CD011935.pub2-BIB0202|cit202","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003231","article-title":"Intravesical Bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer [updated in 2015 and then withdrawn]","author":"Shelley","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD011935.pub2-BIB0203|cit203","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011935","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin versus mitomycin C for Ta and T1 bladder cancer","author":"Schmidt","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD011935.pub2-BIB0204|cit204","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003231.pub2","article-title":"WITHDRAWN: Intravesical Bacillus Calmette-Guerin versus mitomycin C for Ta and T I bladder cancer","author":"Shelley","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD011935.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T23:01:16Z","timestamp":1628550076000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD011935.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Urology Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,1,8]]},"references-count":204,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011935.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,8]]}}}